Remebot
Leading the Way in Robotic Neurosurgery

Since its establishment in 2010, Remebot has emerged as one of the most influential players in the field of neurosurgical robotics. Headquartered in Beijing, with R&D roots tracing back to 1997, the company has consistently adhered to a philosophy of deeply integrating technological innovation with clinical needs. To date, Remebot has completed over 50,000 clinical procedures and is deployed in more than 550 hospitals worldwide, making it not only a benchmark for "Intelligent Manufacturing in China" but also a significant force shaping the future of global neurosurgery.

Remebot’s core competitiveness stems from two pillars: close clinical collaboration and independent mastery of core technologies. The company insists on co-developing solutions with neurosurgeons, ensuring its products address real surgical challenges rather than theoretical possibilities. At the same time, by building its own technological system, Remebot has successfully eliminated dependence on imported components, enabling rapid and precise innovation.

The result of this strategy is the company’s pioneering "Brain-Eye-Hand" system architecture, a first-of-its-kind in the industry.

Offering a Full Matrix of Systems

The Reme-Studio^® AI Surgical Planning System serves as the "Brain," enabling one-click registration, fusion segmentation, and surgical planning. It intelligently segments personalized whole-brain maps covering 95 fine-grained brain subregions, as well as intracranial hematomas, tumors, edema, and functional nuclei, while automatically planning safe surgical paths. The Reme-Vision^® Multispectral Tracking Platform acts as the "Eye," achieving sub-millimeter accuracy (<0.1mm). It supports both optical and infrared markers and features surgical scene reconstruction. The Reme-Explorer Large-Reach Robotic Arm functions as the "Hand," offering six degrees of freedom for fully automated operation and sensitive force feedback.

Together, these elements provide surgeons with precision, speed, and confidence in procedures where the margin for error is nearly zero.

Remebot’s product family—ranging from theRM-100 and RM-200 to the RM-50, RM-260, RM-150, and RM-50T/B—caters to hospitals across the spectrum, from top-tier medical centers to smaller county-level facilities. This breadth of coverage is one of the company's key strengths in the Asian market, where affordability and adaptability are just as crucial as sophistication.

By offering a comprehensive range of systems, Remebot strikes a balance between performance and cost-effectiveness, ensuring that advanced neurosurgical care is accessible to institutions of all levels.

Helping Turn First-Time Adopters into Advocates

The journey to widespread adoption, however, is not without obstacles. Robotic surgery systems are often associated with high upfront costs, steep learning curves, and insufficient technical support. Remebot has worked deliberately to address these barriers. By keeping research and development in-house and ensuring engineering compatibility with a broad range of consumables and imaging equipment, including CT, MRI, and C-arm systems, the company has significantly reduced system costs.

Ease of use is equally central. AI-driven auto-segmentation, one-click planning, and a 20-second marker-free "Super Scan" registration process that takes roughly twenty seconds help flatten the learning curve and shorten training cycles.

Providers also find reassurance in Remebot’s comprehensive support system. Through initiatives such as the Remebot Academy and a nationwide service network, the company ensures that hospitals not only acquire the technology but also feel confident in using it over the long term. This combination of affordability, usability, and support has helped turn first-time adopters into advocates.

Developing the Most Advanced Surgical Robots

Hospitals that integrate Remebot systems often highlight three core benefits. These are unmatched clinical precision, streamlined workflows, and measurable improvements in patient outcomes. Precision of less than 0.1mm inspires trust when operating in the most delicate parts of the brain. AI-driven workflows reduce cognitive load and procedure times, allowing surgeons to focus on what matters most. Patients, in turn, experience faster recoveries and fewer complications.

These tangible outcomes strengthen long-term trust, reinforcing adoption across hospitals. In the words of Dr. Liu Da, the company’s founder and chairman, “Our goal is to develop the most advanced surgical robots and ensure that these solutions are accessible to as many hospitals as possible, regardless of their size or location.”

Clinical adaptability has been another factor in Remebot’s success. The systems support a wide variety of procedures, from deep brain stimulation and stereoelectroencephalography to intracranial biopsies and hematoma evacuations.For grassroots hospitals with limited neurosurgical expertise, the AI-powered planning system enables doctors to perform advanced surgeries safely and effectively.

Meanwhile, top-tier hospitals can utilize specialized modules for neuro-endoscopy, spinal surgery, and skull base procedures. These advanced features include endoscopic navigation, spinal navigation, and master-slave teleoperation, designed to meet the most complex surgical needs.

Balancing Speed and Rigor

Innovation at Remebot does not stop with current products. The company continues to refine automation and expand the scope of its systems. Its self-developed multispectral tracking platform offers a resolution of 4096×3000, maintaining accuracy at less than 0.1mm.

New modules under development integrate technologies such as panoramic navigation, path roaming, real-time visual tracking, and virtual dual-scope, expanding the horizons of minimally invasive neurosurgery. These advances ensure Remebot remains relevant while staying ahead in a competitive and fast-moving field.

The company places strong emphasis on compliance. With six NMPA certificates already secured, Remebot designs its products to meet international standards, including ISO 13485 and IEC 60601. Quality and regulatory alignment are embedded from the earliest stages of research and development. By integrating compliance into the DNA of innovation, Remebot manages to accelerate product iteration without compromising safety or clinical effectiveness. This careful balance of speed and rigor adds weight to the company’s credibility in both domestic and international markets.

Creating a Cycle of Innovation

Global milestones reinforce this credibility. In March 2024, Remebot achieved a historic first in Kazakhstan with the RM-200 system, enabling the country’s first robot-assisted neurosurgery. Within months, local surgeons were independently performing dozens of procedures, demonstrating both the reliability and accessibility of the platform.

Yet Kazakhstan is only one chapter in a broader story. Remebot also played a pioneering role in performing world’s first 5G remote DBS surgery, a breakthrough that proved the viability of combining advanced robotics with next-generation telecommunications. With its expansion into Central Asia and adoption across more than 550 hospitals, Remebot is bringing high-precision neurosurgery to places where it had previously been impossible.

At the heart of this progress lies a structured innovation ecosystem. Remebot maintains what it calls an “industry-university-research-medicine” alliance. Neurosurgeons are not only end-users but co-creators, working alongside engineers in the early stages of R&D and leading clinical trials of new modules. The company participates in national key research projects and gathers continuous feedback through programs like the Remebot Academy.

This closed-loop approach ensures that products evolve in lockstep with real clinical needs, creating a cycle of innovation grounded in practice rather than theory.

Creating a Collaborative Ecosystem

Looking ahead, Remebot is not resting on its achievements. The company is committed to democratizing high-precision neurosurgery, extending access beyond national borders and into global markets.

By combining affordability, precision, and clinical adaptability, Remebot positions itself as a provider of intelligent, cost-effective solutions that carry the mark of ‘Intelligent Manufacturing in China’.

From its first breakthroughs in the early 2000s to its present status as a leader in neurosurgical robotics, Remebot has remained guided by a consistent vision that technology should serve patients and empower doctors.

By embedding compliance into innovation, building trust with providers, and fostering a collaborative ecosystem, the company has demonstrated that the future of neurosurgery is not just about machines, but about people—the surgeons who operate them and the patients whose lives depend on them.